SPOTLIGHT: Merck exec denies Vioxx payola

Merck's former marketing chief defended the company's practice of giving research grants to doctors, denying that it was an attempt to generate positive buzz for Vioxx with the payouts. The testimony came in the first of thousands of Vioxx cases to go to trial. Story

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.